Autoimmune hepatitis and primary sclerosing cholangitis after direct-acting antiviral treatment for hepatitis C virus: A case report

doi:10.4254/wjh.v16.i2.286

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 16, Issue 2

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (2054)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-3) series, Tables (1-3) series.

Item

Count

PDF

WORD

HTML

1130

Figures (1-3)

168

Tables (1-3)

182

Sum=1556

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

167

Download

284

Sum=451

Feb 27, 2024 (publication date) through Jan 1, 2025

Times Cited of This Article

Times Cited (2)

Journal Information of This Article

Publication Name

World Journal of Hepatology

ISSN

1948-5182

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Case Report

World J Hepatol. Feb 27, 2024; 16(2): 286-293
Published online Feb 27, 2024. doi: 10.4254/wjh.v16.i2.286

Table 2 Blood test results (antinuclear antibody and antismooth muscle antibody)

Blood test	ANA	ASMA
Before DAAs (SOF/LDV) therapy	< 20	< 20
After DAAs (SOF/LDV) therapy	40	20
SVR 12	40	160
SVR 24	80	640

ANA: Antinuclear antibody; ASMA: Antismooth muscle antibody; DAA: Direct antiviral agent; SOF: Sofosbuvir; LDV: Ledipasvir; SVR: Sustained virological response.

Citation: Morihisa Y, Chung H, Towatari S, Yamashita D, Inokuma T. Autoimmune hepatitis and primary sclerosing cholangitis after direct-acting antiviral treatment for hepatitis C virus: A case report. World J Hepatol 2024; 16(2): 286-293
URL: https://www.wjgnet.com/1948-5182/full/v16/i2/286.htm
DOI: https://dx.doi.org/10.4254/wjh.v16.i2.286